Eccogene
PrivateLast Round
Strategic
Nov 9, 2023
Est. Valuation
$498M
Total Funding Raised
$238.8M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Eccogene operates in Healthcare & Life Sciences and is based in Shanghai. Its latest recorded funding round was a Strategic round in November 2023.
Eccogene is a clinical-stage biopharmaceutical company that develops next-generation oral small molecule therapeutics for chronic cardiometabolic and inflammatory conditions.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Eccogene Comparables
Compare Eccogene with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Regor Therapeutics Group | 86% | |
| Kailera Therapeutics | 84% | |
| Structure Therapeutics | 84% |
For institutional investors. Book with your work email.
Eccogene Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | Nov 9, 2023 | ||||
| Series B | Jun 11, 2023 | ||||
| Series A Extension | Dec 22, 2020 | ||||
| Series A | Sep 7, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Eccogene Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| New Alliance Capital | Series B |
| TF Capital | Series A |
| 健壹资本 | Series A |
| Huajin Capital | Series B |
| Huagai Capital | Series A Extension |
| Qingsong Capital | Series B, Series A Extension |
| Oriza Seed Venture Capital | Series B, Series A Extension |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 6, 2026
Will present preclinical data at ObesityWeek 2026.
- Nov 6, 2026
ECC1542 data to be presented at ObesityWeek® 2026.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventNov 6, 2026
Eccogene plans to present preclinical data on ECC1542, a small-molecule amylin and calcitonin receptor agonist, at ObesityWeek(R) 2026 in Maryland from Nov 14th to 17th '26.
For institutional investors. Book with your work email.
Eccogene Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Eccogene's valuation, stock price, and market status.
Is Eccogene a public or private company?
Eccogene is a private company.
What is the current stock price of Eccogene?
Eccogene is a private company, so its shares have no public market price. Caplight tracks Eccogene's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Eccogene worth (valuation)?
Eccogene's valuation is estimated at $498.0M based on funding round data.
Can I buy Eccogene stock?
Eccogene shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Eccogene's last funding round?
Eccogene's most recent funding round was Strategic on November 9, 2023.
Who are the main investors in Eccogene?
Key investors in Eccogene include New Alliance Capital, 健壹资本.
Will Eccogene IPO soon?
No public IPO plans have been announced for Eccogene.
How can I track Eccogene secondary market activity?
Caplight tracks bids, offers, and trades in Eccogene's shares on secondary markets.